---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000062"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:10:20.643974+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M

## Summary
- Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).
- Net loss $19.0M ($0.14/share); cash $87.4M at March 31, 2024 (up from $72.5M).
- Entered exclusive license with Amgen for XeriJect teprotumumab; up to $75M milestones plus royalties.
- Entered collaboration with Beta Bionics for XeriSol glucagon in bi-hormonal pumps.
- Tightened FY 2024 total revenue guidance to $175M-$200M; lowered Hayfin debt rate by 2.05%.

## SEC filing metadata
- accession: 0001867096-24-000062
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/0001867096-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/xers-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000062
- JSON: https://secwatch.observer/filing/0001867096-24-000062.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000062.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $40,638, net income $19.0 million, or $0.14 per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $40,638
  - Net income: $19.0 million, or $0.14 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: 13,085 12,755 330 2.6 Recorlev 10,599 4,477 6,122 136.7 Product revenue, net 40,263 32,265 7,998 24.8 Royalty, contract and other revenue 375 931 (556) (59.7) Total revenue $ 40,638 $ 33,196 $ 7,442 22.4 Commercial Products • Gvoke® : First quarter net revenue was $16.6 million as compared to $15.0 million in the first quarter of 2023 – an increase of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/0001867096-24-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.